Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q4 EPS of $3.52, $0.66 better than the analyst estimate of $2.86. Revenue for the quarter came in at $81.1 million versus the consensus estimate of $86.13 million.

• Total revenue for the fourth quarter of 2016 grew 346% to $81.1 million;
  • Product sales increased to $9.1 million compared to $2.9 million in Q4 2015;
  • Royalty income increased to $32.0 million compared to $0.3 million in Q4 2015;
  • License and other income increased to $40.0 million compared to $15 million in Q4 2015;
• $52.9 million in total operating expenses during the quarter included approximately $15.6 million related to accelerated and non-recurring expenses; including $12.3 million related to R&D and $3.3 million in accelerated Sales and Marketing expense related to Ryanodex for EHS marketing activities:
  • R&D expense increased to $16.7 million compared to $8.8 in Q4 2015, which included $12.3 million related to accelerated and non-recurring expenses;
  • Sales & Marketing expense increased to $17.4 million compared to $5.6 in Q4 2015, which included $3.3 million related to accelerated spending as referenced above;
• A tax benefit of $29 million was recorded during the fourth quarter driven by our reversal of the valuation allowance against the Company’s net deferred tax asset;
• Q4 2016 income before income tax benefit was $28.3 million; and,
• Q4 2016 net income was $57.3 million, or $3.75 per basic and $3.52 per diluted share, compared to net income of $1.2 million, or $0.08 per basic and $0.07 per diluted share in Q4 2015.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.